ep adj dilut ep
valu usd unless otherwis note
becton dickinson compani
execut bard deal stock
view report better-than-expect result
manag updat guidanc larg line
think expect stock perform mainli driven
manag abil execut cost/revenu synergi associ
bard deal
comfort manag revenu growth
constant-curr growth y/i expect
weight exclud dispens chang hurrican
impact fx revenu guidanc y/i consist
target manag laid acquisit announc
underli constant-curr basi legaci expect
grow y/i bard expect grow y/i
report revenu includ bard expect
y/i includ benefit fx current rate look
bit conserv divest revenu
believ high end manag ep guidanc
achiev manag ep guidanc includ bard
y/i includ fx y/i currency-
neutral basi manag expect increment benefit
stronger flu season larg off-set increment resin
cost adjust dispens chang manag ep
guidanc line mid-teen y/i annual ep growth target
laid deal announc oper margin expans guidanc
tax rate guidanc
better manag initi think owe tax reform
rais estim reflect bard close rais
revenu estim y/i
constant currenc account bard deal favor
fx cash ep estim move higher y/i
separ revenu estim incl bard
y/i constant currenc cash ep estim
y/i pt move impli ebitda
stock perform execut bard revenue/cost
synergi manag continu expect low-single-digit ep
accret bard also reiter high-single-digit
ep accret target bard line model
assum cost synergi
assum cost synergi weight
heavili toward sg vs cog particularli near term
execut cost synergi crucial manag guidanc
assum annual oper margin expans
separ potenti upsid may aris tax synergi well
revenu synergi latter could begin
price prior trade day market close estimate unless otherwis note
becton dickinson compani
expect perform line peers/sector
believ compani solid outlook larg reflect
acquisit add complementari product portfolio
medic busi posit global
leader medic manag patient safeti
solut expans market like infus
pump autom dispens infect prevent
addit see potenti revenu synergi
carefus deal strong intern presenc
particularli emerg market total sale
emerg market note time
acquisit carefus sale
portfolio limit overlap bard deal give
multi-year cost-cut opportun access bard
temperatur manag product biosurgeri home
care expect bard transact increas
ep growth trajectori mid-teen y/i appear
reason us also expect deal gener
annual pre-tax cost synergi
revenu synergi begin target
annual pre-tax cost synergi assum
reduct bard total cog oper expens vs
carefus
stock perform execut bard
revenue/cost synergi manag continu expect
low-single-digit ep accret bard also
reiter high-single-digit ep accret target
bard line model assum
cost synergi
assum cost synergi weight
heavili toward sg vs cog particularli
near term execut cost synergi crucial
manag guidanc assum annual
oper margin expans separ
potenti upsid may aris tax synergi well
revenu synergi latter could begin
exhibit becton dickinson compani
bloomberg capit market estim upside/downside/target
base case price target base
line large-cap md peer group
base case scenario model organ top-lin growth
rang combin compani bdx bard
scenario assum achiev synergi
bard bard organ top-lin growth
rang also assum stand-alone organ
top-lin growth bottom line model
ep growth low-to-mid teen y/i includ bard
upsid scenario assum share could trade
high next month upsid scenario
model organ top-lin growth includ bard
scenario assum achiev synergi
bard bard organ top-lin growth
rang also assum stand-alone organ
top-lin growth bottom line model
ep growth high-teen y/i includ bard
downsid scenario assum share could trade
low next month model organ
top-lin growth rang includ bard
scenario assum meet cost
synergi target rang bard bard organ top-lin
growth slow rang assum revenu
tax synergi bard downsid scenario
bottom line model ep growth double-digit y/i
becton dickinson compani
price target base pro-forma ebitda estim
combin compani bard target ev/ebitda multipl line larg
cap md peer group averag expect post strong top-
bottom-lin growth low-to-mid teen y/i next sever year
high leverag post bard deal pro-forma leverag close price target support
sector perform rate
risk rate price target
delay and/or declin govern fund and/or capit spend increas competit
compani key market particularli diagnost fluctuat foreign currenc
failur integr acquisit unforeseen chang reimburs practic outcom
on-going lawsuit volatil emerg market unforeseen difficulti implement
compani erp system
becton dickinson co bd lead global supplier safety-engin product
inject infus therapi sampl collect surgeri sharp dispos bd also global
leader clinic flow cytometri strong global presenc microbiolog molecular
test cytolog complet acquisit carefus mid march
acquisit bard late decemb
becton dickinson compani
becton dickinson compani
